HCA Healthcare (HCA)
(Delayed Data from NYSE)
$384.95 USD
-3.03 (-0.78%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $384.70 -0.25 (-0.06%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
HCA 384.95 -3.03(-0.78%)
Will HCA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HCA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCA
2 Sector ETFs & Stocks to Bet on Following August Jobs Data
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
HCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
Zacks.com featured highlights include Vertiv, Charles River Associates, Cabot, Leidos and HCA Healthcare
Other News for HCA
Top Medical Stocks To Hedge Against The September Effect
Boeing downgraded, Southwest upgraded: Wall Street's top analyst calls
Jefferies Sticks to Their Buy Rating for HCA Healthcare (HCA)
HCA Healthcare initiated with neutral view at Morgan Stanley, here's why
IN BRIEF: Illumina celebrates US FDA approval of cancer biomarker test